Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24774763 | 0.91 | GAA (0.37) | GAATDP1RBP4 | |
| SCHEMBL24774768 | 0.88 | CHRNA7 (0.38) | RBP4 | |
| SCHEMBL25613517 | 0.85 | RIPK1 (0.38) | GAATDP1RBP4 | |
| SCHEMBL19423526 | 0.82 | GAA (0.47) | GAATDP1RBP4HTR2CHCRTR1 | |
| SCHEMBL24776098 | 0.81 | ALDH1A1 (0.43) | GAA | |
| SCHEMBL17987098 | 0.81 | CHRNB2 (0.53) | GAATDP1RBP4HTR2C | |
| SCHEMBL24775975 | 0.81 | ALDH1A1 (0.43) | GAA | |
| SCHEMBL24775456 | 0.80 | HSP90AA1 (0.44) | HTR2C | |
| SCHEMBL24775457 | 0.80 | HSP90AA1 (0.44) | HTR2C | |
| SCHEMBL24775973 | 0.80 | CHRNA7 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | GAA 1460/4885TDP1 2571/4885RBP4 3016/4885 |
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | GAA 1765/4885TDP1 2551/4885RBP4 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.